An Article Summarized by CNBC
Novo Nordisk is partnering with telehealth companies Hims & Hers Health, Ro, and LifeMD to offer its weight loss drug Wegovy directly to U.S. patients now that the drug is no longer in short supply. The move comes as legal restrictions tighten on cheaper compounded versions of Wegovy, and the company aims to increase access and convenience by allowing patients to obtain prescriptions and have the drug delivered to their homes via platforms like NovoCare. Hims & Hers will offer Wegovy starting at $599 per month with added care services, while Ro will offer it at $499 per month, emphasizing accessibility for patients without insurance.
This collaboration signals a major shift in how obesity treatments may be delivered, highlighting the growing role of telehealth in pharmaceutical access and compliance with FDA regulations. Hims & Hers, which previously offered compounded semaglutide, is aligning with regulatory standards while still advocating for consumer access. Novo Nordisk’s approach also underlines a broader industry trend toward direct-to-consumer models, offering competitive pricing and support services to retain patients and curb reliance on unregulated compounded alternatives.
For the full article: https://www.cnbc.com/2025/04/29/novo-nordisk-wegovy-telehealth.html
